|
|
J Clin Invest. 1984 October; 74(4): 1540–1544. doi: 10.1172/JCI111568. | PMCID: PMC425325 |
Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man. N H Bell, S Shaw, and R T Turner Abstract Previous in vitro studies in rachitic rat liver suggested that 1,25-dihydroxyvitamin D inhibits the hepatic production of 25-hydroxyvitamin D (25-OHD). An investigation therefore was carried out in eight normal subjects to determine whether concomitant administration of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] would alter the response of serum 25-OHD to challenge with vitamin D. In control studies, vitamin D, 100,000 U/d for 4 d, significantly increased mean serum 25-OHD, from 26.3 +/- 2.9 to 66.7 +/- 12.6 ng/ml (P less than 0.01). In contrast, 1,25(OH)2D3, 2 micrograms/d for 4 d, completely prevented an increase in serum 25-OHD in response to the same dose of vitamin D in the same individuals (25.1 +/- 2.2 vs. 27.4 +/- 5.3 ng/ml, NS). In a post-control study in seven of the normal subjects, vitamin D again significantly increased mean serum 25-OHD, from 18.2 +/- 3.1 to 42.8 +/- 4.7 ng/ml (P less than 0.001). In each of the three studies, mean serum calcium, phosphorus, and creatinine did not change and remained within the normal range. Whereas mean urinary calcium did not change in response to vitamin D alone during the 4 d of the two control studies, it increased significantly in the study in which vitamin D and 1,25(OH)2D3 were given together. A dose-response inhibition of the response of serum 25-OHD to vitamin D by 1,25(OH)2D3 was demonstrated in two of the normal subjects. The results provide evidence that 1,25(OH)2D3 inhibits the hepatic synthesis of its precursor 25-OHD in man. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (692K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. These references are in PubMed. This may not be the complete list of references from this article. - Baran DT, Milne ML. 1,25 dihydroxyvitamin D-induced inhibition of 3H-25 hydroxyvitamin D production by the rachitic rat liver in vitro. Calcif Tissue Int. 1983 Jul;35(4-5):461–464. [PubMed]
- Taylor AB, Stern PH, Bell NH. Abnormal regulation of circulating 25-hydroxyvitamin D in the Williams syndrome. N Engl J Med. 1982 Apr 22;306(16):972–975. [PubMed]
- Baginski ES, Marie SS, Clark WL, Zak B. Direct microdetermination of serum calcium. Clin Chim Acta. 1973 Jun 14;46(1):49–54. [PubMed]
- Bartels H, Böhmer M. Eine Mikromethode zur Kreatininbestimmung. Clin Chim Acta. 1971 Mar;32(1):81–85. [PubMed]
- Dorantes LM, Arnaud SB, Arnaud CD. Importance of the isolation of 25-hydroxyvitamin D before assay. J Lab Clin Med. 1978 May;91(5):791–796. [PubMed]
- Bell NH, Stern PH, Pantzer E, Sinha TK, DeLuca HF. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J Clin Invest. 1979 Jul;64(1):218–225. [PubMed]
- Reinhardt TA, Horst RL, Orf JW, Hollis BW. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab. 1984 Jan;58(1):91–98. [PubMed]
- Mason RS, Lissner D, Posen S, Norman AW. Blood concentrations of dihydroxylated vitamin D metabolites after an oral dose. Br Med J. 1980 Feb 16;280(6212):449–450. [PubMed]
- Stern PH, De Olazabal J, Bell NH. Evidence for abnormal regulation of circulating 1 alpha,25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism. J Clin Invest. 1980 Oct;66(4):852–855. [PubMed]
- Stern PH, Taylor AB, Bell NH, Epstein S. Demonstration that circulating 1 alpha, 25-dihydroxyvitamin D is loosely regulated in normal children. J Clin Invest. 1981 Nov;68(5):1374–1377. [PubMed]
- Hughes MR, Baylink DJ, Jones PG, Haussler MR. Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3. J Clin Invest. 1976 Jul;58(1):61–70. [PubMed]
- Haussler MR, Baylink DJ, Hughes MR, Brumbaugh PF, Wergedal JE, Shen FH, Nielsen RL, Counts SJ, Bursac KM, McCain TA. The assay of 1alpha,25-dihydroxyvitamin D3: physiologic and pathologic modulation of circulating hormone levels. Clin Endocrinol (Oxf). 1976;5 Suppl:151S–165S. [PubMed]
- Kaplan RA, Haussler MR, Deftos LJ, Bone H, Pak CY. The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest. 1977 May;59(5):756–760. [PubMed]
- Lambert PW, Hollis BW, Bell NH, Epstein S. Demonstration of a lack of change in serum 1 alpha,25-dihydroxyvitamin D in response to parathyroid extract in pseudohypoparathyroidism. J Clin Invest. 1980 Oct;66(4):782–791. [PubMed]
- Streck WF, Waterhouse C, Haddad JG. Glucocorticoid effects in vitamin D intoxication. Arch Intern Med. 1979 Sep;139(9):974–977. [PubMed]
- Norman DA, Fordtran JS, Brinkley LJ, Zerwekh JE, Nicar MJ, Strowig SM, Pak CY. Jejunal and ileal adaptation to alterations in dietary calcium: changes in calcium and magnesium absorption and pathogenetic role of parathyroid hormone and 1,25-dihydroxyvitamin D. J Clin Invest. 1981 Jun;67(6):1599–1603. [PubMed]
- Zerwekh JE, Glass K, Jowsey J, Pak CY. An unique form of osteomalacia associated with end organ refractoriness to 1,25-dihydroxyvitamin D and apparent defective synthesis of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 1979 Aug;49(2):171–175. [PubMed]
- Loré F, Di Cairano G, Periti P, Caniggia A. Effect of the administration of 1,25-dihydroxyvitamin D3 on serum levels of 25-hydroxyvitamin D in postmenopausal osteoporosis. Calcif Tissue Int. 1982;34(6):539–541. [PubMed]
- Prince MJ, Schaeffer PC, Goldsmith RS, Chausmer AB. Hyperphosphatemic tumoral calcinosis: association with elevation of serum 1,25-dihydroxycholecalciferol concentrations. Ann Intern Med. 1982 May;96(5):586–591. [PubMed]
- Papapoulos SE, Clemens TL, Fraher LJ, Lewin IG, Sandler LM, O'Riordan JL. 1, 25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. Lancet. 1979 Mar 24;1(8117):627–630. [PubMed]
- Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest. 1983 Nov;72(5):1856–1860. [PubMed]
- Kantarjian HM, Saad MF, Estey EH, Sellin RV, Samaan NA. Hypercalcemia in disseminated candidiasis. Am J Med. 1983 Apr;74(4):721–724. [PubMed]
- Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CY. Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med. 1984 Jan;100(1):1–6. [PubMed]
|
This article has been